Introduction: Concurrent chemoradiotherapy (CRT) is standard therapy for locally advanced NSCLC (LA-NSCLC) patients. This study was performed to examine thoracic radiotherapy (TRT) parameters and their impact on patient survival.
Conclusions: For LA-NSCLC patients treated with concurrent CRT, IF-TRT was associated with significantly better survival than ENI-TRT. TRT total and BED dose levels were not significantly associated with patient survival. Future progress will require research focusing on better systemic therapy and TRT.
Introduction
Lung cancer is the most common malignancy resulting in death. In the United States alone during 2017 it was estimated that lung cancer was diagnosed in 222,500 patients and resulted in 157,700 deaths. 1 Approximately 20% of all lung cancers are locally advanced or stage III at diagnosis. 2 NSCLC comprises approximately 85% of all lung cancers with only a minority of patients amenable to resection. Thus, systemic therapy and radiotherapy are used for most patients. 2 Significant progress has been made since the 1960s in the treatment of locally advanced (stage III) NSCLC (LA-NSCLC). 3, 4 In the 1960s, a randomized trial found that thoracic radiotherapy (TRT) resulted in modestly better patient survival than observation. 5 Before the common usage of chemoradiotherapy (CRT), another randomized trial determined that the regimen of 60 Gy in 30 daily fractions achieved better local control than lesser TRT doses conventionally fractionationed. 6 In the 1990s, induction chemotherapy followed by TRT achieved better patient survival than TRT alone. 7, 8 Later, randomized trials found that concurrent CRT resulted in better survival then sequential CRT. 9, 10 In 2015, a large trial determined that concurrent chemotherapy with TRT doses of 60 Gy in 30 daily fractions resulted in better survival than the same chemotherapy with 74 Gy in 37 daily fractions. 11 Thus, progress has been made and patient outcomes have improved. 3, 4 Additionally, a recent randomized trial found that progression-free survival was further improved in stage III NSCLC patients if they received immunotherapy (durvalumab) after CRT. 12 Despite progress, controversies remain in the treatment of LA-NSCLC patients. In the radiation therapy of LA-NSCLC, certain basic questions have not been clearly answered. For example, what dosefractionation pattern is best? Should TRT only target radiographically visible disease with involved-field TRT (IF-TRT) or should one also irradiate adjacent lymph nodes that have potential microscopic disease but are not radiographically abnormal with elective nodal irradiation (ENI)? To address these questions, we performed this pooled analysis of the outcomes of patients participating in the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) trials. The main goal of this analysis was to establish which radiotherapy targeting and dosing strategies were associated with improved patient survival. This information would provide data helpful in designing future trials and developing evidence-based TRT guidelines that define the standard of care in treating LA-NSCLC.
Methods and Materials
To address these fundamental radiation oncology questions regarding the treatment of LA-NSCLC, we performed this pooled analysis of the outcomes of 3600 LA-NSCLC patients participating in 16 trials. These trials are shown in Table 1 .
Data-sharing agreements were developed with the various cooperative groups to perform this analysis. Individual patient data (IPD) were obtained for unresectable LA-NSCLC patients in NCTN trials. All therapy was delivered between 1990 and 2012. A centralized database was developed including these patients' data to potentially identify optimal dosefractionation and target volumes for TRT within various CRT programs. Only trials including concurrent CRT with or without additional chemotherapy before or after concurrent CRT were included. Excluded were trials specifically written for high-risk patients with poor performance status (PS) and those with targeted therapy without concurrent CRT. The primary endpoint of this analysis was overall survival. The duration of survival was defined as the period between registration or randomization and death. Treatment patterns were divided as follows: induction chemotherapy followed by concurrent CRT, concurrent CRT alone, and concurrent CRT followed by consolidation chemotherapy.
Radiotherapy variables evaluated included nodal coverage strategy (IF-TRT versus ENI-TRT), total TRT dose, and biologically effective dose (BED). IF-TRT most commonly refers to radiotherapy administered to the primary lesion and radiographically involved regional lymph nodes (>1 cm in short diameter or metabolically active nodes on positron-emission tomography [PET], when available). ENI includes radiotherapy to the primary lesion, radiographically involved nodes, and adjacent uninvolved nodes (most often including the ipsilateral hilum, much of the mediastinum, and in some trials the supraclavicular nodes). The BED formula (shown below) accounts for Patients received cisplatin with gemcitabine, paclitaxel or vinorlebine induction therapy followed by same cisplatin-based therapy with concurrent TRT. Only patients with stage 3 disease included. Data from Dillman et al., 8 Clamon et al., 21 Vokes et al., 22 Akerley et al., 23 Vokes et al., 24 Socinsky et al., 25 Ready et al., 26 Govindan et al., 27 Schild et al., 28 Zhao et al., 29 Movsas et al., 30 Bradley et al., 31 Blumenshein et al., 32 Bradley et al., 33 Hoang et al., 34 and Kelly et al. 35 CALGB, Cancer and Leukemia Group B; NCCTG, North Central Cancer Treatment Group; RTOG, Radiation Therapy Oncology Group; ECOG, Eastern Cooperative Oncology Group; SWOG, Southwest Oncology Group; TRT, thoracic radiation; BID, twice daily.
the efficacy provided by individual dose-fractionation programs related to the overall time radiotherapy is delivered compared to the potential doubling time of tumor cells. The potential doubling time (Tpot) for NSCLC has been reported in the radiobiology literature to range from 2.2 days to 8.9 days. [15] [16] [17] We used 5.6 days as the Tpot value for the purposes of this analysis. Thus, a break in the TRT decreases the BED and the potential efficacy of the regimen because a greater overall time of radiotherapy (RT) allows for tumor repopulation to occur.
Statistical Analysis
The association between RT and other patient characteristics were tested using the chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables. Kaplan-Meier curves were used to estimate survival. 18 The distribution difference of survival for various groups was tested by log-rank test, and the association of RT-related variables with survival were further quantified by unadjusted and adjusted hazard ratios (HRs), estimated with 95% confidence intervals (CIs) using univariable and multivariable Cox models. 19, 20 Frailty Cox models were used with study trials as random effect to account for the clustering effect of patients within studies and the between-trial variance that could not be captured by covariates. 19, 20 Candidate covariates used for backward selection were treatment pattern, age group, PS, sex, race, weight loss, histology, number of chemotherapy agents, and recent trial or not (accrual closed before or after 2000). Treatment pattern and RT variables were included in all adjusted models because they corresponded to the effects of primary interest. The other variables included in the final model for the survival analyses were treatment pattern, age group, PS, sex, weight loss, and number of chemotherapy agents. The adjusted HRs from the pooled analysis were compared with the adjusted HRs of each trial. The p values testing specific effects of these regression models were based on the Wald test. All p values reported are two-sided and were not adjusted for multiple comparisons. The study was approved by the Duke University Institutional Review Board. Data management and statistical analyses were performed by statisticians at the Duke Department of Biostatistics and Bioinformatics using SAS (version 9.3; SAS Institute, Cary, North Carolina) and R (version 3.2; R Foundation, Vienna, Austria) statistical software.
Results
IPD from 3600 patients participating in 16 trials were included in this pooled analysis ( Fig. 1 ) ( Table 1) . 8, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 46 Patient characteristics are found in Table 2 . The average patient age was 62 years and 64% were men. Zubrod PS was 0-1 in 99.1% of patients and 88.8% were white. Tumor histologies were described as adenocarcinoma in 33.3%, squamous cell cancer in 35.4%, and other in the remaining patients. It was common during that time to report the tissue as NSCLC without being more specific. The cohort was split almost evenly between stages IIIa and IIIb disease and 83% had no significant weight loss in the past 6 months. TRT field design (IF versus ENI) used was specifically described in each protocol. The majority of patients (n ¼ 2844, 79%) were treated with ENI-TRT ( Table 2 ) and this TRT targeting strategy was more common in early trials. Total doses ranged from 60 Gy to 74 Gy and most treatment was given daily but some studies included twice-daily TRT arms (Table 3) .
Seven trials included induction chemotherapy followed by concurrent CRT, four trials included concurrent CRT followed by consolidation chemotherapy, four trials used concurrent CRT alone, and one trial randomly assigned patients between induction chemotherapy followed by concurrent CRT and concurrent CRT. Specific chemotherapy agents used in each trial are found on (Fig. 2) .
Total TRT doses ranged from 60 Gy to 74Gy and most treatment was delivered with once-daily fractionation (Table 3) . Patients were divided into three dose groups: low total dose, 60 Gy (1322 patients, 37%), medium total dose, >60 Gy to 66 Gy (1422 patients, 39%), and high total dose, >66 Gy to 74 Gy (856 patients, 24% months in the medium-dose group, and 19 months in the high-dose group. The 5-year survival rate was 17% in the low-dose group, 16% in the medium-dose group, and 17% in the high-dose group (Fig. 3 , survival with 95% CIs).
BED was grouped as follows: low (<55.5Gy 10 , 747 patients, 21%), medium (55.5 Gy 10 , 1197 patients, 33%), or high (>55.5 Gy 10 , 1656 patients, 46%). The median survival time was 19 months for the low-BED patients, 18 months for the medium-BED patients, and 16-months weight loss, stage, and number of systemic agents. With reference to the low-BED group, the multivariable HRs were 1.00 (95% CI: 0.85-1.18) for the medium-BED group and 1.10 (95% CI: 0.93-1.31) for the high-BED group. Thus, BED was not significantly associated with survival (Fig. 4 , survival with 95% CIs). This study was performed to examine specific RT parameters used in LA-NSCLC cooperative group trials with the goal of determining if these factors were associated with survival. This data could be useful when choosing specific targeting strategies (IF-RT versus ENI) and doses of radiation when planning concurrent CRT.
The present study found that CRT using IF-RT was associated with significantly better survival than ENI with median survival of 24 months and 16 months, respectively. Previous randomized studies that have investigated IF-RT compared to ENI have been relatively small, lacking sufficient power to detect a clearly significant difference in overall survival. Our findings generally agree with the three randomized CRT trials that compared IF-RT to ENI. [36] [37] [38] Yuan et al. 38 included 200 patients with LA-NSCLC treated with concurrent CRT and randomized to either an IF-TRT or ENI arm. A total of 4 to 6 cycles of cisplatinbased chemotherapy were delivered, and concurrent CRT was started after the second cycle of chemotherapy. Conventionally fractionated (1.8 Gy to 2 Gy daily) threedimensional TRT was used to deliver 68 Gy to 74 Gy with IF-TRT or 60 Gy to 64 Gy with ENI. The 2-and 5-year survival rates were 26% and 18% for the ENI arm and 39% and 25% for the IF-TRT arm, respectively. Only the 2-year survival rates were significantly different (p ¼ 0.048). The median survival was 15.0 months with ENI and 20.0 months with IF-TRT.
Yang et al. 38 included 55 LA-NSCLC patients who first received 4 cycles of induction chemotherapy and then were randomized to ENI (mean dose, 58.4 Gy) or IF-TRT (mean dose, 65.8 Gy). The median survival was 15 months with IF-TRT and 13 months with ENI (p ¼ 0.084).
Chen et al. 36 randomized 85 patients to IF-RT or ENI delivering a median dose of 60 Gy in each arm. Induction chemotherapy (paclitaxel and carboplatin) was administered intravenously for 2 cycles. This was followed by CRT with concurrent weekly paclitaxel. The 2-and 3-year survival rates were 53%, and 37%, respectively, in the IF-RT arm, compared to 34.9%, and 30.3% in the ENI arm (p ¼ 0.08). The median survival was 28 months with IF-TRT and 17 months with ENI. Debate continued following these randomized trials that reported significant or nearly significant findings.
39-41
Li et al. 42 evaluated the three randomized trials and three additional retrospective studies in a meta-analysis.
This was done to provide better evidence on the incidence of elective nodal failure (ENF) with IF-TRT or ENI. ENF was defined as nodal failure without local failure in initially univolved nodes within regions that received prophylactic irradiation with ENI but were not treated with IF-TRT. When combining all six studies, the incidence of ENF was 5.5% with IF-RT and 3.4% with ENI (relative risk ¼ 1.15, p ¼ 0.64).
Cooperative group trials used both IF-RT and ENI as it was unknown which was better. These were compared in the present pooled analysis to provide objective evidence regarding survival. On both univariable and multivariable analyses, ENI was associated with poorer survival. This data provides reasonably strong evidence that IF-TRT should be the preferred strategy. Reasons for this difference in survival may be related to toxicity or immunosuppression as IF-TRT avoids irradiating large clinically uninvolved nodal regions mainly within the mediastinum. This decreases the dose delivered to normal surrounding normal tissues such as heart, lungs, esophagus, and the immune system. Of these, the most important may be the heart as exposure to therapeutic irradiation has been associated with severe toxicity and poorer survival. 11, 43, 44 In one large modern trial, multivariable analysis revealed that poorer survival was associated with higher prescribed radiation dose, esophageal toxicity, target volume, and heart V5 and V30 (% of heart volume receiving !5 Gy or !30 Gy, respectively). 11 In a large retrospective study, Speirs reported that the 2-year survival of LA-NSCLC lung cancer patients was 46.8% for those with a heart V50 of <25% versus 26.7% for those with greater heart exposure (p <0.0001). 43 Additionally, the dose administered to the immune system (lymphoid system, circulating white blood cells, and marrow) appears important. Jin et al. 45 found that the dose to immunologic system was significantly associated with poorer survival of LA-NSCLC patients. Over time, more trials have been written to include IF-TRT due to concerns of toxicity with the recognition that the survival rates reported in studies using IF-TRT appeared favorable. These findings also led some to create guidelines recommending IF-TRT. 48 While this study focused on survival as the primary endpoint, we plan a separate analysis focused specifically on toxicity.
With respect to the evaluation of TRT dose, the present analysis found no significant association between dose and survival. We divided the total dose into three dose groups: low total dose 60 Gy, medium total dose >60 Gy to 66 Gy, and high total dose >66 Gy to 74 Gy. With reference to the low-dose group, the multivariable HRs were 1.08 for the medium-dose group and 1.12 for the high-dose group. This suggested that the lower dose range appeared numerically more favorable but not significantly so within the context of the concurrent CRT used in these trials. Numerically greater HRs in higherdose groups agrees, in general, with the findings of Ramroth et al. 49 They performed a meta-analysis including 3795 patients participating in 25 randomized trials comparing TRT doses. They found that when treatment included concurrent CRT, higher TRT doses resulted in significantly worse survival (HR ¼ 1.2, p ¼ 0.02). They believed that this was due to increased toxicity with concurrent CRT using higher TRT doses. Interestingly, they recommended future CRT research focusing on TRT dose escalation using newer technology to reduce toxicity.
We also examined the possible relationships between survival and TRT BED. The BED formula accounts for the length and fractionation of a TRT course. Similar to TRT dose, the BED was not significantly associated with patient survival.
It was generally believed that dose and fractionation affect the survival of stage III NSCLC patients. However, with the RT technology used in these trials (primarily 3-dimensional TRT and intensity-modulated RT [IMRT]), escalation of total dose alone with conventional fractionation did not improve survival. 11 It is possible that altered fractionation programs that use either multiple daily fractions or fewer larger fractions may improve survival. In the past, programs including multiple daily doses of TRT were administered and found to positively impact survival but mainly in patients who received TRT alone. 49, 50 One CRT trial using hypofractionation reported very favorable results. 47 The best arm included concurrent hypofractioned IF-TRT (66 Gy in 24 daily treatments) and daily cisplatin resulting in a median survival of 33 months and a 5-year survival rate of 37%.
Strengths of the present study were the large size of the cohort (N¼3600) and the prospective nature of the original trials. Limitations include the retrospective nature of this analysis. The use of IF-RT was most common in the more modern series. However, the multivariable analysis was designed to adjust for the timing of various trials and several other factors. We did not compare IMRT to 3D TRT as IMRT was only used for some of the patients who participated in a single trial. PET was required in only one trial (Cancer and Leukemia Group B [CALGB] 30407) and was permissible in the other IF-TRT trials (Table 3) . However, there were no PET data within our database so we could not examine potential influence on outcome. PET scans can potentially influence outcome through stage migration and were performed more frequently in the recent studies that included IF-TRT.
In conclusion, this pooled analysis of LA-NSCLC patients treated with concurrent CRT found that IF-TRT resulted in significantly better survival than ENI. Additionally, we did not detect a significant association between TRT dose level and survival. Therefore, for the purposes of general practice and trial development, the use of IF-TRT and 60 Gy in 2 Gy daily fractions should be considered the standard of care for CRT of LA-NSCLC. Future progress in the treatment of LA-NSCLC is dependent on research examining immunotherapy, targeted therapy, improved imaging, adaptive radiotherapy, simultaneous integrated boost techniques, novel dosefractionation regimens, and charged particle therapy.
